Literature DB >> 15271392

Biology of chronic myelogenous leukemia--signaling pathways of initiation and transformation.

Junia V Melo1, Michael W N Deininger.   

Abstract

Chronic myeloid leukemia (CML) is caused by the Bcr-Abl oncoprotein,the product of the t(9;22) chromosomal translocation that generates the Philadelphia chromosome. Different disease phenotypes are associated with each of the three Bcr-Abl isoforms: p190Bcr-Abl, p210Bcr-Abl, and p230Bcr-Abl all of which have a constitutively activated tyrosine kinase. Mechanisms associated with malignant transformation include altered cellular adhesion, activation of mitogenic signaling pathways, inhibition of apoptosis, and proteasomal degradation of physiologically important cellular proteins.CML is subject to an inexorable progression from an "indolent" chronic phase to a terminal blast crisis. Disease progression is presumed to be associated with the phenomenon of genomic instability.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15271392     DOI: 10.1016/j.hoc.2004.03.008

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  41 in total

1.  Inhibition of class II phosphoinositide 3-kinase gamma expression by p185(Bcr-Abl) contributes to impaired chemotaxis and aberrant homing of leukemic cells.

Authors:  Weidong Yu; Xiaolin Sun; Hongxing Tang; Yunxia Tao; Zonghan Dai
Journal:  Leuk Lymphoma       Date:  2010-06

2.  Genetic aberrations in childhood acute lymphoblastic leukaemia: application of high-density single nucleotide polymorphism array.

Authors:  Sarina Sulong
Journal:  Malays J Med Sci       Date:  2010-07

3.  Genomic instability in chronic myeloid leukemia: targets for therapy?

Authors:  N Muvarak; P Nagaria; F V Rassool
Journal:  Curr Hematol Malig Rep       Date:  2012-06       Impact factor: 3.952

4.  Imatinib plasma trough concentration and its correlation with characteristics and response in Chinese CML patients.

Authors:  Qiu-bai Li; Chao Chen; Zhi-chao Chen; Hong-xiang Wang; Yan-lin Wu; Yong You; Ping Zou
Journal:  Acta Pharmacol Sin       Date:  2010-07-19       Impact factor: 6.150

5.  Rapamycin combined with celecoxib enhanced antitumor effects of mono treatment on chronic myelogenous leukemia cells through downregulating mTOR pathway.

Authors:  Jie Li; Liying Xue; Hongling Hao; Ruoyu Li; Jianmin Luo
Journal:  Tumour Biol       Date:  2014-03-30

6.  Transcription and signalling pathways involved in BCR-ABL-mediated misregulation of 24p3 and 24p3R.

Authors:  Zhi Sheng; Shu-Zong Wang; Michael R Green
Journal:  EMBO J       Date:  2009-02-19       Impact factor: 11.598

7.  FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.

Authors:  Paolo Neviani; Ramasamy Santhanam; Joshua J Oaks; Anna M Eiring; Mario Notari; Bradley W Blaser; Shujun Liu; Rossana Trotta; Natarajan Muthusamy; Carlo Gambacorti-Passerini; Brian J Druker; Jorge Cortes; Guido Marcucci; Ching-Shih Chen; Nicole M Verrills; Denis C Roy; Michael A Caligiuri; Clara D Bloomfield; John C Byrd; Danilo Perrotti
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

Review 8.  Dysregulation of apoptotic signaling in cancer: molecular mechanisms and therapeutic opportunities.

Authors:  Jessica Plati; Octavian Bucur; Roya Khosravi-Far
Journal:  J Cell Biochem       Date:  2008-07-01       Impact factor: 4.429

9.  Identification of basophils as a major source of hepatocyte growth factor in chronic myeloid leukemia: a novel mechanism of BCR-ABL1-independent disease progression.

Authors:  Sabine Cerny-Reiterer; Viviane Ghanim; Gregor Hoermann; Karl J Aichberger; Harald Herrmann; Leonhard Muellauer; Andreas Repa; Christian Sillaber; Andrew F Walls; Matthias Mayerhofer; Peter Valent
Journal:  Neoplasia       Date:  2012-07       Impact factor: 5.715

Review 10.  Biology-driven cancer drug development: back to the future.

Authors:  Christopher J Lord; Alan Ashworth
Journal:  BMC Biol       Date:  2010-04-12       Impact factor: 7.431

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.